Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Avantis International Small Cap Value ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Avantis International Small Cap Value ETF trades at $110.2. The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AVDV | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $110.40 |
52-Week Low | $205.48 | $83.89 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
AVDV trades at $110.28, up 0.75% today, with a bullish technical signal from moving averages but caution from overbought oscillators. The stock shows strength near resistance at $110, supported by positive media coverage highlighting international small-cap value performance and a forthcoming dividend. Recent news notes a 21% return since November 2025, driven by commodity exposure that has since cooled.
Outlook remains positive due to strong momentum and dividend yield, but risks include overbought conditions and reliance on international markets. Investors should weigh technical indicators against fundamental growth prospects in developed ex-US small caps.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
